The HIV community will soon be seeing twice-yearly data from the PURPOSE 1 clinical trial. Rena Capa Building Preliminary results have shown it to be 100%...
The HIV-1 capsid inhibitor lenacapavir, administered as a twice-yearly injection, was 100% effective in preventing HIV infection in women at high risk of infection, according to...
Extended release oral tablet formulation Ketamine Showing promise against treatment-resistant disease depression (TRD) Phase 2 proof-of-concept study results suggest. In this study, sustained-release ketamine administered twice...
Urinary tract infections are one of the most common bacterial infections. It is painful, requires antibiotic treatment, and recurs in 20% to 30% of cases. Because...
semaglutide Related drugs for weight loss have been adopted as obesity drugs in recent months. They also raise serious questions for hospital clinicians who believe the...
Editor’s Note: For the latest news and guidance on COVID-19, see Medscape’s article. Coronavirus Resource Center. A new study warns against using donor hearts infected with...
Recent Comments